Skip to main content
SpringerLink
Log in

Management of Biochemical Recurrence After Localized Treatment for Prostate Cancer

  • Chapter
  • First Online:
Management of Prostate Cancer

Part of the book series: Current Clinical Urology ((CCU))

  • 1448 Accesses

Abstract

Prostate cancer remains the most prevalent solid organ tumor among U.S. men with an increasing percentage of men being diagnosed with localized disease. Current standard treatment options include active surveillance, surgery, and radiation with or without the use of hormonal therapy. Unfortunately, a number of men whether or not they have high-risk features will experience a biochemical recurrence (BCR). This presents an interesting situation for the patient and managing clinician as for the need for further imaging and/or need for secondary therapy. We provide a review of the management of BCR after localized treatment for prostate cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59(4):225–49.

    Article  PubMed  Google Scholar 

  2. Cooperberg MR, Broering JM, Litwin MS, et al. The contemporary management of prostate cancer in the United States: lessons from the cancer of the prostate strategic urologic research endeavor (CapSURE), a national disease registry. J Urol. 2004;171(4): 1393–401.

    Article  PubMed  Google Scholar 

  3. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999;281(17):1591–7.

    Article  PubMed  CAS  Google Scholar 

  4. Stephenson AJ, Scardino PT, Eastham JA, et al. Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Clin Oncol. 2005;23(28):7005–12.

    Article  PubMed  Google Scholar 

  5. Catalona WJ, Smith DS. 5-year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer. J Urol. 1994;152(5 Pt 2): 1837–42.

    PubMed  CAS  Google Scholar 

  6. Trock BJ, Han M, Freedland SJ, et al. Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA. 2008;299(23):2760–9.

    Article  PubMed  CAS  Google Scholar 

  7. Thompson IM, Tangen CM, Paradelo J, et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol. 2009;181(3): 956–62.

    Article  PubMed  Google Scholar 

  8. Choueiri TK, Chen MH, D’Amico AV, et al. Impact of postoperative prostate-specific antigen disease recurrence and the use of salvage therapy on the risk of death. Cancer. 2010;116(8):1887–92.

    Article  PubMed  Google Scholar 

  9. D’Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280(11):969–74.

    Article  PubMed  Google Scholar 

  10. Agarwal PK, Sadetsky N, Konety BR, Resnick MI, Carroll PR. Treatment failure after primary and salvage therapy for prostate cancer: likelihood, patterns of care, and outcomes. Cancer. 2008;112(2): 307–14.

    Article  PubMed  Google Scholar 

  11. Walsh PC, Donker PJ. Impotence following radical prostatectomy: insight into etiology and prevention. J Urol. 1982;128(3):492–7.

    PubMed  CAS  Google Scholar 

  12. Han M, Partin AW, Pound CR, Epstein JI, Walsh PC. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am. 2001;28(3): 555–65.

    Article  PubMed  CAS  Google Scholar 

  13. Kupelian PA, Katcher J, Levin HS, Klein EA. Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy. Int J Radiat Oncol Biol Phys. 1997;37(5):1043–52.

    Article  PubMed  CAS  Google Scholar 

  14. Pound CR, Partin AW, Epstein JI, Walsh PC. Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control. Urol Clin North Am. 1997;24(2): 395–406.

    Article  PubMed  CAS  Google Scholar 

  15. Swindle P, Eastham JA, Ohori M, et al. Do margins matter? The prognostic significance of positive surgical margins in radical prostatectomy specimens. J Urol. 2005;174(3):903–7.

    Article  PubMed  Google Scholar 

  16. Oesterling JE, Chan DW, Epstein JI, et al. Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy. J Urol. 1988;139(4): 766–72.

    PubMed  CAS  Google Scholar 

  17. Cookson MS, Aus G, Burnett AL, et al. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes. J Urol. 2007;177(2):540–5.

    Article  PubMed  CAS  Google Scholar 

  18. Stephenson AJ, Kattan MW, Eastham JA, et al. Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition. J Clin Oncol. 2006;24(24): 3973–8.

    Article  PubMed  CAS  Google Scholar 

  19. Cronin AM, Godoy G, Vickers AJ. Definition of biochemical recurrence after radical prostatectomy does not substantially impact prognostic factor estimates. J Urol. 2010;183(3):984–9.

    Article  PubMed  Google Scholar 

  20. Amling CL, Bergstralh EJ, Blute ML, Slezak JM, Zincke H. Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point? J Urol. 2001;165(4): 1146–51.

    Article  PubMed  CAS  Google Scholar 

  21. Kuban DA, Thames HD, Levy LB, et al. Long-term multi-institutional analysis of stage T1-T2 prostate cancer treated with radiotherapy in the PSA era. Int J Radiat Oncol Biol Phys. 2003;57(4):915–28.

    Article  PubMed  Google Scholar 

  22. American Society for Therapeutic Radiology and Oncology Consensus Panel. Consensus statement: guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys. 1997;37(5):1035–41.

    Google Scholar 

  23. Stephenson AJ, Shariat SF, Zelefsky MJ, et al. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA. 2004;291(11): 1325–32.

    Article  PubMed  CAS  Google Scholar 

  24. Roach III M, Hanks G, Thames Jr H, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006;65(4):965–74.

    Article  PubMed  Google Scholar 

  25. Abramowitz MC, Li T, Buyyounouski MK, et al. The Phoenix definition of biochemical failure predicts for overall survival in patients with prostate cancer. Cancer. 2008;112(1):55–60.

    Article  PubMed  Google Scholar 

  26. Partin AW, Pearson JD, Landis PK, et al. Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases. Urology. 1994;43(5): 649–59.

    Article  PubMed  CAS  Google Scholar 

  27. Taylor JM, Yu M, Sandler HM. Individualized predictions of disease progression following radiation therapy for prostate cancer. J Clin Oncol. 2005;23(4): 816–25.

    Article  PubMed  Google Scholar 

  28. Freedland SJ, Humphreys EB, Mangold LA, et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA. 2005;294(4):433–9.

    Article  PubMed  CAS  Google Scholar 

  29. Lee AK, D’Amico AV. Utility of prostate-specific antigen kinetics in addition to clinical factors in the selection of patients for salvage local therapy. J Clin Oncol. 2005;23(32):8192–7.

    Article  PubMed  Google Scholar 

  30. D’Amico AV, Renshaw AA, Sussman B, Chen MH. Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy. JAMA. 2005;294(4):440–7.

    Article  PubMed  Google Scholar 

  31. Hanlon AL, Diratzouian H, Hanks GE. Posttreatment prostate-specific antigen nadir highly predictive of distant failure and death from prostate cancer. Int J Radiat Oncol Biol Phys. 2002;53(2):297–303.

    Article  PubMed  Google Scholar 

  32. Pollack A, Zagars GK, Antolak JA, Kuban DA, Rosen II. Prostate biopsy status and PSA nadir level as early surrogates for treatment failure: analysis of a prostate cancer randomized radiation dose escalation trial. Int J Radiat Oncol Biol Phys. 2002;54(3): 677–85.

    Article  PubMed  Google Scholar 

  33. Lee WR, Hanlon AL, Hanks GE. Prostate specific antigen nadir following external beam radiation therapy for clinically localized prostate cancer: the relationship between nadir level and disease-free survival. J Urol. 1996;156(2 Pt 1):450–3.

    PubMed  CAS  Google Scholar 

  34. Zietman AL, Tibbs MK, Dallow KC, et al. Use of PSA nadir to predict subsequent biochemical outcome following external beam radiation therapy for T1-2 adenocarcinoma of the prostate. Radiother Oncol. 1996;40(2):159–62.

    Article  PubMed  CAS  Google Scholar 

  35. Cher ML, Bianco Jr FJ, Lam JS, et al. Limited role of radionuclide bone scintigraphy in patients with prostate specific antigen elevations after radical prostatectomy. J Urol. 1998;160(4):1387–91.

    Article  PubMed  CAS  Google Scholar 

  36. Okotie OT, Aronson WJ, Wieder JA, et al. Predictors of metastatic disease in men with biochemical failure following radical prostatectomy. J Urol. 2004;171(6 Pt 1):2260–4.

    Article  PubMed  Google Scholar 

  37. Kane CJ, Amling CL, Johnstone PA, et al. Limited value of bone scintigraphy and computed tomography in assessing biochemical failure after radical prostatectomy. Urology. 2003;61(3):607–11.

    Article  PubMed  Google Scholar 

  38. Beresford MJ, Gillatt D, Benson RJ, Ajithkumar T. A systematic review of the role of imaging before salvage radiotherapy for post-prostatectomy biochemical recurrence. Clin Oncol (R Coll Radiol). 2010;22(1):46–55.

    Article  CAS  Google Scholar 

  39. Dotan ZA, Bianco Jr FJ, Rabbani F, et al. Pattern of prostate-specific antigen (PSA) failure dictates the probability of a positive bone scan in patients with an increasing PSA after radical prostatectomy. J Clin Oncol. 2005;23(9):1962–8.

    Article  PubMed  Google Scholar 

  40. Choueiri TK, Dreicer R, Paciorek A, Carroll PR, Konety B. A model that predicts the probability of positive imaging in prostate cancer cases with biochemical failure after initial definitive local therapy. J Urol. 2008;179(3):906–10; discussion 910.

    Google Scholar 

  41. Lecouvet FE, Geukens D, Stainier A, et al. Magnetic resonance imaging of the axial skeleton for detecting bone metastases in patients with high-risk prostate cancer: diagnostic and cost-effectiveness and comparison with current detection strategies. J Clin Oncol. 2007;25(22):3281–7.

    Article  PubMed  Google Scholar 

  42. Silverman JM, Krebs TL. MR imaging evaluation with a transrectal surface coil of local recurrence of prostatic cancer in men who have undergone radical prostatectomy. AJR Am J Roentgenol. 1997;168(2): 379–85.

    PubMed  CAS  Google Scholar 

  43. Sella T, Schwartz LH, Swindle PW, et al. Suspected local recurrence after radical prostatectomy: endorectal coil MR imaging. Radiology. 2004;231(2):379–85.

    Article  PubMed  Google Scholar 

  44. Sala E, Eberhardt SC, Akin O, et al. Endorectal MR imaging before salvage prostatectomy: tumor localization and staging. Radiology. 2006;238(1): 176–83.

    Article  PubMed  Google Scholar 

  45. Kahn D, Williams RD, Seldin DW, et al. Radioimmunoscintigraphy with 111indium labeled CYT-356 for the detection of occult prostate cancer recurrence. J Urol. 1994;152(5 Pt 1):1490–5.

    PubMed  CAS  Google Scholar 

  46. Hinkle GH, Burgers JK, Neal CE, et al. Multicenter radioimmunoscintigraphic evaluation of patients with prostate carcinoma using indium-111 capromab pendetide. Cancer. 1998;83(4):739–47.

    Article  PubMed  CAS  Google Scholar 

  47. Quintana JC, Blend MJ. The dual-isotope ProstaScint imaging procedure: clinical experience and staging results in 145 patients. Clin Nucl Med. 2000;25(1): 33–40.

    Article  PubMed  CAS  Google Scholar 

  48. Proano JM, Sodee DB, Resnick MI, Einstein DB. The impact of a negative (111)indium-capromab pendetide scan before salvage radiotherapy. J Urol. 2006;175(5):1668–72.

    Article  PubMed  Google Scholar 

  49. Shekarriz B, Upadhyay J, Wood Jr DP, et al. Vesicourethral anastomosis biopsy after radical prostatectomy: predictive value of prostate-specific antigen and pathologic stage. Urology. 1999;54(6): 1044–8.

    Article  PubMed  CAS  Google Scholar 

  50. Foster LS, Jajodia P, Fournier Jr G, Shinohara K, Carroll P, Narayan P. The value of prostate specific antigen and transrectal ultrasound guided biopsy in detecting prostatic fossa recurrences following radical prostatectomy. J Urol. 1993;149(5):1024–8.

    PubMed  CAS  Google Scholar 

  51. Crook J, Malone S, Perry G, Bahadur Y, Robertson S, Abdolell M. Postradiotherapy prostate biopsies: what do they really mean? Results for 498 patients. Int J Radiat Oncol Biol Phys. 2000;48(2):355–67.

    Article  PubMed  CAS  Google Scholar 

  52. Bostwick DG, Egbert BM, Fajardo LF. Radiation injury of the normal and neoplastic prostate. Am J Surg Pathol. 1982;6(6):541–51.

    Article  PubMed  CAS  Google Scholar 

  53. Stephenson AJ, Eastham JA. Role of salvage radical prostatectomy for recurrent prostate cancer after radiation therapy. J Clin Oncol. 2005;23(32): 8198–203.

    Article  PubMed  Google Scholar 

  54. Crook JM, Malone S, Perry G, et al. Twenty-four-month postradiation prostate biopsies are strongly predictive of 7-year disease-free survival: results from a Canadian randomized trial. Cancer. 2009;115(3): 673–9.

    Article  PubMed  Google Scholar 

  55. Cadeddu JA, Partin AW, DeWeese TL, Walsh PC. Long-term results of radiation therapy for prostate cancer recurrence following radical prostatectomy. J Urol. 1998;159(1):173–7; discussion 177–8.

    Google Scholar 

  56. Pisansky TM, Kozelsky TF, Myers RP, et al. Radiotherapy for isolated serum prostate specific antigen elevation after prostatectomy for prostate cancer. J Urol. 2000;163(3):845–50.

    Article  PubMed  CAS  Google Scholar 

  57. Katz MS, Zelefsky MJ, Venkatraman ES, Fuks Z, Hummer A, Leibel SA. Predictors of biochemical outcome with salvage conformal radiotherapy after radical prostatectomy for prostate cancer. J Clin Oncol. 2003;21(3):483–9.

    Article  PubMed  Google Scholar 

  58. Eulau SM, Tate DJ, Stamey TA, Bagshaw MA, Hancock SL. Effect of combined transient androgen deprivation and irradiation following radical prostatectomy for prostatic cancer. Int J Radiat Oncol Biol Phys. 1998;41(4):735–40.

    Article  PubMed  CAS  Google Scholar 

  59. Cheung R, Kamat AM, de Crevoisier R, et al. Outcome of salvage radiotherapy for biochemical failure after radical prostatectomy with or without hormonal therapy. Int J Radiat Oncol Biol Phys. 2005;63(1): 134–40.

    Article  PubMed  Google Scholar 

  60. Hayes SB, Pollack A. Parameters for treatment decisions for salvage radiation therapy. J Clin Oncol. 2005;23(32):8204–11.

    Article  PubMed  Google Scholar 

  61. Stephenson AJ, Scardino PT, Kattan MW, et al. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol. 2007;25(15):2035–41.

    Article  PubMed  Google Scholar 

  62. Zelefsky MJ, Aschkenasy E, Kelsen S, Leibel SA. Tolerance and early outcome results of postprostatectomy three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys. 1997;39(2):327–33.

    Article  PubMed  CAS  Google Scholar 

  63. MacDonald OK, Schild SE, Vora S, et al. Salvage radiotherapy for men with isolated rising PSA or locally palpable recurrence after radical prostatectomy: do outcomes differ? Urology. 2004;64(4): 760–4.

    Article  PubMed  Google Scholar 

  64. Duchesne GM, Dowling C, Frydenberg M, et al. Outcome, morbidity, and prognostic factors in post-prostatectomy radiotherapy: an Australian multicenter study. Urology. 2003;61(1):179–83.

    Article  PubMed  Google Scholar 

  65. Van Cangh PJ, Richard F, Lorge F, et al. Adjuvant radiation therapy does not cause urinary incontinence after radical prostatectomy: results of a prospective randomized study. J Urol. 1998;159(1): 164–6.

    Article  PubMed  Google Scholar 

  66. Syndikus I, Pickles T, Kostashuk E, Sullivan LD. Postoperative radiotherapy for stage pT3 carcinoma of the prostate: improved local control. J Urol. 1996;155(6):1983–6.

    Article  PubMed  CAS  Google Scholar 

  67. Formenti SC, Lieskovsky G, Skinner D, Tsao-Wei DD, Groshen S, Petrovich Z. Update on impact of moderate dose of adjuvant radiation on urinary continence and sexual potency in prostate cancer patients treated with nerve-sparing prostatectomy. Urology. 2000;56(3):453–8.

    Article  PubMed  CAS  Google Scholar 

  68. Bianco Jr FJ, Scardino PT, Stephenson AJ, Diblasio CJ, Fearn PA, Eastham JA. Long-term oncologic results of salvage radical prostatectomy for locally recurrent prostate cancer after radiotherapy. Int J Radiat Oncol Biol Phys. 2005;62(2):448–53.

    Article  PubMed  Google Scholar 

  69. Zelefsky MJ, Ben-Porat L, Scher HI, et al. Outcome predictors for the increasing PSA state after definitive external-beam radiotherapy for prostate cancer. J Clin Oncol. 2005;23(4):826–31.

    Article  PubMed  Google Scholar 

  70. Zagars GK, Pollack A, von Eschenbach AC. Prostate cancer and radiation therapy—the message conveyed by serum prostate-specific antigen. Int J Radiat Oncol Biol Phys. 1995;33(1):23–35.

    Article  PubMed  CAS  Google Scholar 

  71. Boris RS, Bhandari A, Krane LS, Eun D, Kaul S, Peabody JO. Salvage robotic-assisted radical prostatectomy: initial results and early report of outcomes. BJU Int. 2009;103(7):952–6.

    Article  PubMed  CAS  Google Scholar 

  72. Kaouk JH, Hafron J, Goel R, Haber GP, Jones JS. Robotic salvage retropubic prostatectomy after radiation/brachytherapy: initial results. BJU Int. 2008;102(1): 93–6.

    Article  PubMed  Google Scholar 

  73. Ward JF, Pagliaro LC, Pisters LL. Salvage therapy for radiorecurrent prostate cancer. Curr Probl Cancer. 2008;32(6):242–71.

    Article  PubMed  Google Scholar 

  74. Rogers E, Ohori M, Kassabian VS, Wheeler TM, Scardino PT. Salvage radical prostatectomy: outcome measured by serum prostate specific antigen levels. J Urol. 1995;153(1):104–10.

    Article  PubMed  CAS  Google Scholar 

  75. Kimura M, Mouraviev V, Tsivian M, Mayes JM, Satoh T, Polascik TJ. Current salvage methods for recurrent prostate cancer after failure of primary radiotherapy. BJU Int. 2010;105(2):191–201.

    Article  PubMed  CAS  Google Scholar 

  76. Touma NJ, Izawa JI, Chin JL. Current status of local salvage therapies following radiation failure for prostate cancer. J Urol. 2005;173(2):373–9.

    Article  PubMed  Google Scholar 

  77. Masterson TA, Stephenson AJ, Scardino PT, Eastham JA. Recovery of erectile function after salvage radical prostatectomy for locally recurrent prostate cancer after radiotherapy. Urology. 2005;66(3):623–6.

    Article  PubMed  Google Scholar 

  78. Stephenson AJ, Scardino PT, Bianco Jr FJ, DiBlasio CJ, Fearn PA, Eastham JA. Morbidity and functional outcomes of salvage radical prostatectomy for locally recurrent prostate cancer after radiation therapy. J Urol. 2004;172(6 Pt 1):2239–43.

    Article  PubMed  Google Scholar 

  79. Gheiler EL, Tefilli MV, Tiguert R, et al. Predictors for maximal outcome in patients undergoing salvage surgery for radio-recurrent prostate cancer. Urology. 1998;51(5):789–95.

    Article  PubMed  CAS  Google Scholar 

  80. Chin JL, Pautler SE, Mouraviev V, Touma N, Moore K, Downey DB. Results of salvage cryoablation of the prostate after radiation: identifying predictors of treatment failure and complications. J Urol. 2001;165(6 Pt 1):1937–41; discussion 1932–41.

    Google Scholar 

  81. Izawa JI, Madsen LT, Scott SM, et al. Salvage cryotherapy for recurrent prostate cancer after radiotherapy: variables affecting patient outcome. J Clin Oncol. 2002;20(11):2664–71.

    Article  PubMed  Google Scholar 

  82. Ng CK, Moussa M, Downey DB, Chin JL. Salvage cryoablation of the prostate: followup and analysis of predictive factors for outcome. J Urol. 2007;178(4 Pt 1):1253–57; discussion 1257.

    Google Scholar 

  83. Ismail M, Ahmed S, Kastner C, Davies J. Salvage cryotherapy for recurrent prostate cancer after radiation failure: a prospective case series of the first 100 patients. BJU Int. 2007;100(4):760–4.

    Article  PubMed  Google Scholar 

  84. D’Amico AV. Combined modality staging for clinically localized adenocarcinoma of the prostate as the basis for patient selection for randomized trials of neoadjuvant chemotherapy. Urol Oncol. 2001;6(4):171–2.

    Article  PubMed  Google Scholar 

  85. Pisters LL, Rewcastle JC, Donnelly BJ, Lugnani FM, Katz AE, Jones JS. Salvage prostate cryoablation: initial results from the cryo on-line data registry. J Urol. 2008;180(2):559–63; discussion 554–63.

    Google Scholar 

  86. Pisters LL, von Eschenbach AC, Scott SM, et al. The efficacy and complications of salvage cryotherapy of the prostate. J Urol. 1997;157(3):921–5.

    Article  PubMed  CAS  Google Scholar 

  87. Ghafar MA, Johnson CW, De La Taille A, et al. Salvage cryotherapy using an argon based system for locally recurrent prostate cancer after radiation therapy: the Columbia experience. J Urol. 2001;166(4):1333–7; discussion 1337–8.

    Google Scholar 

  88. Cresswell J, Asterling S, Chaudhary M, Sheikh N, Greene D. Third-generation cryotherapy for prostate cancer in the UK: a prospective study of the early outcomes in primary and recurrent disease. BJU Int. 2006;97(5):969–74.

    Article  PubMed  Google Scholar 

  89. Nguyen PL, D’Amico AV, Lee AK, Suh WW. Patient selection, cancer control, and complications after salvage local therapy for postradiation prostate-specific antigen failure: a systematic review of the literature. Cancer. 2007;110(7):1417–28.

    Article  PubMed  Google Scholar 

  90. Cohen JK. Cryosurgery of the prostate: techniques and indications. Rev Urol. 2004;6 Suppl 4:S20–6.

    PubMed  Google Scholar 

  91. Eisenberg ML, Shinohara K. Partial salvage cryoablation of the prostate for recurrent prostate cancer after radiotherapy failure. Urology. 2008;72(6): 1315–8.

    Article  PubMed  Google Scholar 

  92. Nguyen PL, Chen MH, D’Amico AV, et al. Magnetic resonance image-guided salvage brachytherapy after radiation in select men who initially presented with favorable-risk prostate cancer: a prospective phase 2 study. Cancer. 2007;110(7):1485–92.

    Article  PubMed  Google Scholar 

  93. Grado GL, Collins JM, Kriegshauser JS, et al. Salvage brachytherapy for localized prostate cancer after radiotherapy failure. Urology. 1999;53(1): 2–10.

    Article  PubMed  CAS  Google Scholar 

  94. Koutrouvelis P, Hendricks F, Lailas N, et al. Salvage reimplantation in patient with local recurrent prostate carcinoma after brachytherapy with three dimensional computed tomography-guided permanent pararectal implant. Technol Cancer Res Treat. 2003;2(4):339–44.

    PubMed  Google Scholar 

  95. Tharp M, Hardacre M, Bennett R, Jones WT, Stuhldreher D, Vaught J. Prostate high-dose-rate brachytherapy as salvage treatment of local failure after previous external or permanent seed irradiation for prostate cancer. Brachytherapy. 2008;7(3): 231–6.

    Article  PubMed  Google Scholar 

  96. Lee B, Shinohara K, Weinberg V, et al. Feasibility of high-dose-rate brachytherapy salvage for local prostate cancer recurrence after radiotherapy: the University of California-San Francisco experience. Int J Radiat Oncol Biol Phys. 2007;67(4):1106–12.

    Article  PubMed  Google Scholar 

  97. Nair B, Wilt T, MacDonald R, Rutks I. Early versus deferred androgen suppression in the treatment of advanced prostatic cancer. Cochrane Database Syst Rev. 2002(1):CD003506.

    Google Scholar 

  98. Moul JW, Wu H, Sun L, et al. Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy. J Urol. 2004;171(3):1141–7.

    Article  PubMed  Google Scholar 

  99. Prostate Cancer Trialists’ Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet. 2000;355(9214):1491–8.

    Article  Google Scholar 

  100. Loblaw DA, Virgo KS, Nam R, et al. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol. 2007;25(12): 1596–605.

    Article  PubMed  CAS  Google Scholar 

  101. Kurek R, Renneberg H, Lubben G, Kienle E, Tunn UW. Intermittent complete androgen blockade in PSA relapse after radical prostatectomy and incidental prostate cancer. Eur Urol. 1998;35(Suppl S1):27–31.

    PubMed  Google Scholar 

  102. Seidenfeld J, Samson DJ, Hasselblad V, et al. Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis. Ann Intern Med. 2000;132(7):566–77.

    PubMed  CAS  Google Scholar 

  103. Barqawi AB, Moul JW, Ziada A, Handel L, Crawford ED. Combination of low-dose flutamide and finasteride for PSA-only recurrent prostate cancer after primary therapy. Urology. 2003;62(5):872–6.

    Article  PubMed  Google Scholar 

  104. Picus J, Halabi S, Small E, Hussain A, Philips G, Kaplan E, et al. Long term efficacy of peripheral androgen blockade on prostate cancer: CALGB 9782. J Clin Oncol. 2006;24(Suppl):4573.

    Google Scholar 

  105. Goodin S, Medina P, Capanna T, et al. Effect of docetaxel in patients with hormone-dependent prostate-specific antigen progression after local therapy for prostate cancer. J Clin Oncol. 2005;23(15):3352–7.

    Article  PubMed  CAS  Google Scholar 

  106. Taplin ME, Xie W, Bubley GJ, et al. Docetaxel, estramustine, and 15-month androgen deprivation for men with prostate-specific antigen progression after definitive local therapy for prostate cancer. J Clin Oncol. 2006;24(34):5408–13.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Urologic Oncology, The Center for Cancer Prevention and Treatment at St., Joseph Hospital and Associated Urologists of Orange County, Orange, CA, USA

    Stephen B. Williams

  2. Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute and Brigham and Woman’s Hospital, Boston, MA, USA

    Toni K. Choueiri

Authors
  1. Stephen B. Williams
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Toni K. Choueiri
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stephen B. Williams .

Editor information

Editors and Affiliations

  1. , Glickman Urological and Kidney, Cleveland Clinic, 9500 Euclid Ave, Cleveland, 44195, Ohio, USA

    Eric A. Klein

  2. Cleveland Clinic, Cleveland Clinic Lerner College of Medic, Department of Regional Urology, at Case Western Reserve, Cleveland, 44195, Ohio, USA

    J. Stephen Jones

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Williams, S.B., Choueiri, T.K. (2012). Management of Biochemical Recurrence After Localized Treatment for Prostate Cancer. In: Klein, E., Jones, J. (eds) Management of Prostate Cancer. Current Clinical Urology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-60761-259-9_21

Download citation

  • DOI: https://doi.org/10.1007/978-1-60761-259-9_21

  • Published:

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-60761-258-2

  • Online ISBN: 978-1-60761-259-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation